Patent ID: 7736652

Claim:
An ex vivo pharmaceutical composition comprising: an antibody-immunostimulant fusion protein having an antibody domain and an immunostimulant domain, a disease-related antigen, one or more antigen presenting cells, and a pharmaceutically acceptable carrier or a pharmaceutically acceptable excipient, wherein the fusion protein acts as an effective adjuvant of the disease-related antigen; wherein the antibody-immunostimulant fusion protein comprises antibody specificity against the antigen; wherein the antibody domain comprises an intact antibody, comprising two light chains and two heavy chains, or an antibody fragment, which fragment is selected from the group consisting of an Fab domain, an Fab′ domain, an F(ab′) 2 domain, an scFv domain, and an F(ab) 2 domain; and, wherein the immunostimulant domain comprises an immunostimulant selected from the group consisting of IL-2, IL-12, and GM-CSF.